United States · FDA National Drug Code directory
Contrave Extended-Release
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 51267-890_8e7e5582-7a35-4ec7-85e7-b88a98d1bd23
- Product NDC
- 51267-890
- Form
- TABLET, EXTENDED RELEASE
- Composition / generic term
- naltrexone hydrochloride and bupropion hydrochloride
- Labeler
- Nalpropion Pharmaceuticals LLC
- Marketing category
- NDA
- Marketing start / end (source format)
- 20141022
- Source listing expiry
- 20261231
Source-listed ingredients
- NALTREXONE HYDROCHLORIDE — 8 mg/1
- BUPROPION HYDROCHLORIDE — 90 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (51267-890-07) · 51267-890-07
- 120 TABLET, EXTENDED RELEASE in 1 BOTTLE (51267-890-99) · 51267-890-99
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →